Therapeutic Decision-Making in the Adjuvant Setting in HR+ Breast Cancer : Episode 7

Informed Decision-Making in HR+ Breast Cancer

May 22, 2021

Video

Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.

EP: 1.Optimizing Systemic Therapy for Early-Stage HR+ Breast Cancer

EP: 2.Perioperative Decision-Making in HR+ Breast Cancer

EP: 3.Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer

EP: 4.The Oncotype DX Breast Recurrence Score: Clinical Trial Data

EP: 5.Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer

EP: 6.NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer

Now Viewing

EP: 7.Informed Decision-Making in HR+ Breast Cancer

EP: 8.Neoadjuvant Therapy for HR+ Breast Cancer

EP: 9.Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer

EP: 10.Genomic Testing vs Genetic Testing for HR+ Breast Cancer

EP: 11.The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!